Physician profile
Anshul Agarwal
NPI 1285845743
$1,829.66
in general payments reported to CMS, 2019-2025
16 companies · $631 in 2025
The $631 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2021: $121 · 2022: $129 · 2023: $168 · 2024: $579 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $666.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $229.40 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Lilly USA, LLC | $191.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $188.06 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $119.28 | 2022-2024 | Breztri, Farxiga, Bevespi Aerosphere |
| Medtronic, INC. | $95.45 | 2025 | Venaseal |
| Exact Sciences Corporation | $80.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.13 | 2025 | Ofev |
| Shield Therapeutics INC | $46.60 | 2023-2024 | Accrufer |
| Dexcom, INC. | $40.60 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $33.65 | 2022 | |
| Inspire Medical Systems, INC. | $24.65 | 2025 | Inspire |
| Vanda Pharmaceuticals INC. | $17.65 | 2025 | Ponvory |
| Astellas Pharma US INC | $17.48 | 2024 | Veozah |
| Gilead Sciences, INC. | $14.53 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshul Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.